objectives To identify a standard treatment regime or highly successful procedure for chronic osteomyelitis in low-and middle-income countries.
Introduction
Chronic osteomyelitis remains a difficult condition to treat, both from patient and doctor's point of view. The course of treatment is long and often requires multiple surgeries and a prolonged hospital stay [1] [2] [3] . Definitive eradication is never certain and as a consequence many patients relapse over time. This has significant implications for patient morbidity and self-reliance and a major socio-economic impact. The latter is even more important in low-and middle-income countries (LMICs) where one individual is often the sole caretaker or revenue source for the whole family and chronic osteomyelitis disproportionately affects the young [4] . Also, healthcare systems in LMICs are often low quality, underfunded and difficult to access [5] .
In the Western world, osteomyelitis treatment is gradually changing from a two-stage to a one-stage procedure as the result of new biomaterials entering the market, such as bioactive glass S53P4 (BonAlive â , Bonalive Biomaterials Ltd., Turku, Finland) and Cerament TM G (Bonesupport, Lund, Sweden). These biomaterials allow bone void filling in an infected environment, effectively eliminating the need for a stepped approach, and already have clinical track records showing very good results [6] [7] [8] . It would therefore be interesting to see whether these stateof-the-art materials can also be implemented in healthcare environments with fewer resources, financially as well as structurally. In order to do that, one-first has to have an insight in current treatment standards for chronic osteomyelitis under these conditions.
In this review, we sought to identify a standard treatment regime or highly successful procedure for chronic osteomyelitis in LMICs and to advise on basic needs that have to be met in order to improve the level of care of chronic osteomyelitis in even the most difficult settings.
Methods

Protocol and registration
This systematic review was written according to the PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions [9] .
Eligibility criteria
Prospective and retrospective cohort studies dealing with the treatment or management of chronic osteomyelitis in low-income countries were eligible. All low-income countries were considered for the selection of articles. Case reports and reviews were excluded due to lack of clinical evidence or lack of outcome data, respectively. Article selection was restricted to English, Dutch and German language.
Patients of any age and both genders with chronic osteomyelitis of any type were considered, if treatment occurred in low-income countries. All interventions for the treatment of chronic osteomyelitis were included. Primary outcome measures were recovery or recurrence rate after treatment. Recurrence occurred when additional treatments were necessary subsequently to an already conducted treatment method.
Information sources
Studies were identified by searching the electronic databases PubMed, EMBASE and Web of Science, by scanning the reference list of the chosen articles and by collecting articles from experts. The Cochrane database was reviewed. The last search was conducted on 26 November 2016.
Search
For searching the electronic databases, the following search terms were used: • EMBASE: chronic osteomyelitis; therapy; management; recovery; recurrence; developing countries; developing country; low income countries; low income country; third world; poverty
• Web of Science: chronic osteomyelitis; therapy; management; recovery; recurrence; developing countries; developing country; low income countries; low income country; third world; poverty The full search strategy for PubMed and Web of Science is shown in Appendix S1.
Study selection
One assessed eligibility. First, titles and abstracts were screened for eligibility criteria. If these were met, full-text availabilities were checked. Subsequently, eligibility was assessed a second time based on the full-text article if information was missing in the abstract.
Data
The data were extracted and checked by one reviewer. For the extraction of data, the STROBE statement guidelines for reporting observational studies was used [10] . From each included study, data were obtained on:
• Country where study was performed • Study design • Number and characteristics of patients included (age, gender)
• Type of intervention (pharmaceutical and surgical treatment)
• Period of follow-up • Outcome measure: eradication rate or recurrence rate
Risk of bias in individual studies
The risk of bias in the included studies was assessed using the Cochrane Collaboration's tool for assessing the risk of bias in non-randomised studies. Using this tool, five customised domains (patient selection, quality of methodology, follow-up, data report and other issues) were evaluated for each study and judged as high risk, moderate risk, low risk or unclear risk of bias [11] .
Summary measures
Primary outcome measures were eradication rate or recurrence rate after treatment.
Results
Study selection
Nine articles involving nine studies were identified for qualitative analysis (Figure 1 ). The search of the databases PubMed, EMBASE and Web of Science provided a total of 102 articles. Another nine articles that met the selection criteria were identified. Altogether 111 articles were identified through literature search. After adjusting for duplicates, 83 articles remained. Through screening of articles based on titles and abstracts, 61 articles were excluded because they did not meet the eligibility criteria: 34 articles focussed on a different disease, 17 articles did not contain the appropriate outcome data, six articles dealt with the situation in highincome countries, three articles were not available in English, Dutch or German and one article described an animal study.
After examining the full text of the remaining 24 articles, nine articles were excluded because full text was not available. Three articles did not contain the appropriate outcome data and three articles were case reports. Finally, nine studies met the inclusion criteria and were analysed qualitatively.
Study characteristics
An overview of the study design, inclusion and exclusion criteria per included study is given in Appendix S2. Of the nine finally selected studies, four studies were prospective cohort studies [12] [13] [14] [15] and five studies were retrospective cohort studies [4, [16] [17] [18] [19] 
Participants
The studies involved 1173 patients from Africa (Kenya, Malawi, Nigeria, Congo, Uganda, Ethiopia) and Asia (Nepal, India). All patients were diagnosed with chronic osteomyelitis. The age of the patients ranged from 1 month to 84 years with a mean age of 15 years and a male/female ratio of 714/333; the sex of 153 patients is not specified (Table 1) .
Intervention
In all studies, patients received local surgical interventions at the affected bone sites, including debridement through sequestrectomy, saucerisation or curettage [4, [12] [13] [14] [15] [16] [17] [18] [19] , bone grafting [16] [17] [18] , amputation [4, 16] and the application of local antibiotic delivery systems [13, 15] ( Table 2 ). Additional antibiotic therapy was administered either locally or systemically in most studies [12] [13] [14] [15] [17] [18] [19] . Antibiotic therapy differed considerably among the different studies in terms of antibiotics used, duration of therapy and type of administration (Table 2) . Of the studies with information about the antibiotics used, three administered cloxacillin or flucloxacillin for 4-6 weeks [12, 17, 18] . In one study, vancomycin, cefuroxime and meropenem were given pre-and post-surgically [15] and in two studies, culture-based antibiotics were administered for at least 6 weeks [13, 19] . Ikpeme et al. used antibiotics impregnated in non-degradable polymethylmethacrylate (PMMA) as a local delivery system, whereas Mondal et al. used antibiotic-impregnated bone cement beads [13, 15] . Whereas Mantero et al. treated all included participants with the same intervention [12] , participants in the other studies were treated differently.
Outcome
All nine studies had comparable outcomes. In every study, data about the recovery rate or the percentage of cured patients were collected either as primary or as secondary outcome. Other outcomes were risk factors of osteomyelitis relapse in patients with osteomyelitis of long bones (one study), patient demographics (three studies), site of infection and sequelae (five studies), cultured micro-organisms (three studies), patient function in terms of pre-and post-treatment disability (one study), aetiology of chronic osteomyelitis (two studies), visit of a bonesetter and the use of antibiotics prior to admission to hospital (one study). In two studies, the percentage of surgeries due to osteomyelitis was calculated and in one study, the percentage of hospital stay related to chronic osteomyelitis was also analysed. In most of the studies, no clear difference between primary and secondary outcomes was made. Radiological (X-ray) and serological (eradication of infection) techniques as well as clinical examination were used for the outcome measurement of the recovery rate.
Risk of bias within studies
The critical assessment of the risk of bias within each study is based on the Cochrane Collaboration's tool for assessing the risk of bias in non-randomised studies [11] . Five different entries were evaluated in each study and were judged as low risk (+: 0), moderate risk (+/À: 1), high risk (À: 2) or unclear risk (?: 0.5) ( Table 3) . Those entries include patient selection, the quality of methodology, follow-up, data report and other issues as potential risk of bias due to study design. Using those entries, assessment of selection bias, performance bias, information bias and confounders was possible. A complete overview of the assessment of the risk of bias including the support for the judgement is available in Appendix S3.
Patient selection
In all studies, patients suffering from chronic osteomyelitis were included. In one study, where patients with diaphyseal or metaphyseal osteomyelitis were included, no information was given about the duration of osteomyelitis. Authors mentioned inclusion criteria in every study even though they were not always clearly described. Exclusion criteria were described clearly in five studies. Although the selection of patients was well described most of the time, no better judgement than moderate risk of selection bias could be made due to the study designs. All studies were prospective or retrospective, which are more prone to selection bias than random clinical trials with a random allocation of patients. Only Ikpeme et al. 2013 used a control group, but did not mention the comparability between the control group and the intervention group [13] . One study applied a randomised method for patient selection [4] .
Quality of methods
To assess the risk of performance bias in the included studies, the quality of methods was evaluated. Recurrence or comparable outcomes were defined as the presentation of clinical or radiological symptoms during the follow-up period [12] , the necessity of additional surgical interventions [16] , any further in-patient management during the period of follow-up [17] , recurrence of a discharging sinus within the period of follow-up [13] or using a scale to assess patient function before and after the intervention [18] among almost all studies. A few studies did not define the outcome specifically [4, 14, 15, 19] .
Other reported outcome measurements as risk factors of osteomyelitis were relapse in patients with osteomyelitis of long bones, patient demographics, site of infection and sequelae, cultured micro-organisms, aetiology of chronic osteomyelitis, visit of a bonesetter, the use of antibiotics prior to admission to hospital and the percentage of surgeries and hospital stay due to chronic osteomyelitis were reported. Clinical examination, radiological (X-ray) or haematological (erythrocyte sedimentation) techniques were used as outcome measurements as well as the simple fact of admission to the hospital for the same problem during the follow-up period. Most studies had a clear treatment protocol, which was described precisely. The remaining studies were not clear about the applied interventions and the used co-interventions (antibiotic therapy).
Follow-up
The period of follow-up was described in five of the nine studies. In those studies, patients were followed for at least 12 months after the intervention. Mantero et al. 2011 did not mention the mean period of follow-up. However, it is stated that 90 patients were followed at least for 12 months and six patients were lost before. Possible reasons for loss-to-follow-up were not analysed [12] . In one study, loss-to-follow-up occurred in 44% of all participants and again no analysis for possible reasons was performed [18] . In another study, it is not clear whether loss-to-follow-up occurred [17] . In the remaining four studies, follow-up was not reported at all [4, 14, 16, 19] .
Data report
Mostly, data were discussed well and the outcome measurements were reported. However, confidence intervals were missing most of the time and also statistical analysis was not performed as standard. Even when statistical analysis was performed, different outcome measures than recurrence or recovery rate related to the different interventions were tested. Treatment protocols were not clear in every study and patients received different interventions and co-interventions from which the outcome was not analysed separately. In one study, the same intervention was applied to all patients, in another study, two interventions were compared and in a third study, the same co-intervention (antibiotic therapy) was 
Other issues
In three studies, other sources of bias could be identified. In one study, patients in five hospitals were included and thus, the quality of record keeping varied among those hospitals leading to missing information [4] . For this reason, the risk of information bias rises. Furthermore, accuracy of diagnosis of osteomyelitis varied among those hospitals, leading to a higher risk of performance bias [4] . In another study, patients self-administered antibiotics before admission to hospital. So, the effect of the intervention cannot be attributed to the surgical intervention alone. Here, confounding could occur [14] . Questions about the treatment protocol in the study of Mondal et al. 2015 remain, and thus, it is not clear whether other sources of bias are present [15] .
Results of individual studies
In all nine studies, clear differentiation between primary and secondary outcomes did not occur. The outcome of interest in this review is recurrence or recovery rate. Both outcomes differ considerably among the included studies and were not analysed statistically except in one study. Ikpeme et al. 2013 compared debridement/sequestrectomy combined with a local antibiotic delivery system with debridement/sequestrectomy alone. Additionally, all patients were treated with antibiotics for 6 weeks. The recovery rate of the first intervention was about 77.8%, whereas the recovery rate of the control group was 57.7%. Even if the recovery rate was substantially higher in the intervention group, the difference is not statistically significant (P = 0.208) [13] . In one study, where all patients received the same intervention -sequestrectomy in combination with systemic antibiotic therapy for 6 weeks -recovery rate was 87.8% [12] . Two studies reported recovery rates of 69% and 70%, whereby antibiotics were not administered in the first study but were administered in the second [16, 17] . Lower recovery rates were found in three studies (52%, 63.4%, %66%) [4, 14, 18] . In those three studies, sequestrectomy or saucerisation was used to remove necrotic bone tissue and in one study, antibiotics were given systematically in addition to the surgical treatment [18] .
Remarkably high recovery rates were found in the studies of Mondal et al. 2015 (93%) and Agaja and Ayorinde 2010 (97.3)% [15, 19] . Mondal et al. 2015 used antibiotic cement beads as local antibiotic delivery system next to debridement and administered antibiotics systemically before and after the surgical intervention [15] . Sequestrectomy, saucerisation and curettage were the surgical interventions in the study of Agaja and Ayorinde 2010 which was combined with systemic antibiotic therapy for 6 weeks [19] .
Risk factors of osteomyelitis relapse in patients with osteomyelitis of long bones, patient demographics, site of infection and sequelae, cultured micro-organisms, aetiology of chronic osteomyelitis, visit of a bonesetter and the use of antibiotics prior to admission to hospital were also analysed in the different studies.
According to Mantero et al. 2011 , a risk factor for relapse is metaphyseal osteomyelitis at onset (P < 0.0001). When micro-organisms were present in the osteolytic bone site, Staphylococcus aureus was the most frequent micro-organism (61% [17] , 56.8% in sinus tract and 76% in sequestrum/marrow curettings [13] , 37.6% [19] ). Other detected micro-organisms were Escherichia coli, Streptococcus, Bacillus subtilis, Proteus, Coliforms, Klebsiella, Pseudomonas or even multiple micro-organisms [13, 17, 19] .
In four of the five studies which analysed the affected bone site, tibia and femur were the most frequent affected bones followed by the humerus [13, 16, 17, 19] . Biruk et al. 2007 detected most cases of osteomyelitis in the tibia, followed by the fibula and the femur [14] .
Regarding the economic burden of chronic osteomyelitis in low-income countries, Stanley et al. 2010 and Beckles et al. 2010 both reported that surgeries for osteomyelitis contributed for 3.5 and 6.7% of the surgeries performed in the selected hospitals, respectively [4, 17] . Bed occupancy due to chronic osteomyelitis was about 7.6% of all in-patient days during the study period [17] .
For the individual, treatment of chronic osteomyelitis is economically demanding. In Malawi, the gross domestic product (GDP) per capita was about US$342.6 in 2014 [20] . The per capita total expenditure on health in Malawi in 2014 was about approximately US$29 from which US$12 were household out of pocket spending [21] . This amount resembles 3.5% of the GDP per capita. Assuming that the average spending on health does not include extensive treatments and admission to hospital as it is necessary for the treatment of chronic osteomyelitis, it can be assumed that costs for the treatment of chronic osteomyelitis including admission to hospital and surgery are even higher and resemble a higher percentage of the GDP per capita. For this reason, it is expected that the treatment of chronic osteomyelitis in low-income countries is an enormous economic burden for the individual patient.
Discussion
Summary of evidence
The aim of this systematic review was to compare the efficacy of current treatments of chronic osteomyelitis in lowincome countries to identify the currently most effective treatment. Overall, the evidence of the nine included studies is not sufficiently robust to identify the most effective treatment. Recovery rates differ remarkably (between 52% and 97.7%), as do the different treatment protocols.
The study designs (prospective and retrospective studies) are not optimal to assess the efficacy of a treatment. Actually, randomised clinical trials are preferred for this objective. The designs used in the included studies are more prone to bias, which increases the risk of bias together with the detected weakness of the quality of methodology.
Furthermore, the outcome of main interest for this systematic review, recovery rate or recurrence, was not defined clearly in all nine studies and outcome measurements were not reported in all cases. For this reason, the number of studies with appropriate evidence further decreases.
Only one study tested the outcome of interest statistically without statistical significance. As the other studies did not analyse the outcome measurements of recovery rate and recurrence statistically and additional other weaknesses were found in different studies, the internal validity of most of the selected studies is moderate.
Limitations
Main limitations of the included studies are the great variety of treatment protocols including different periods of follow-up or lacking information, different or missing definitions of recovery/recurrence, different diagnostic tools and the missing statistical analysis of the outcome of interest in this review (recovery rate and recurrence), and missing control groups except in one study.
The limitations of the individual studies result in some of the limitations of this systematic review, such as the low level of evidence, suboptimal methodology and the small number of included studies leading to a small number of patients and the risk of information bias, as two articles about the treatment of chronic osteomyelitis in low-income countries could not be accessed [22, 23] . Another seven articles were excluded due to lacking access. Those articles were mainly published in the 1990s. Thus, it is assumed that data of those articles are not recent enough and that lacking of this information does not contribute to a higher risk of information bias.
Conclusion
The best suitable treatment of chronic osteomyelitis in low-income countries cannot be identified based on this systematic review. It seems that surgical intervention with local antibiotic delivery systems could result in a better recovery rate but two studies with sequestrectomy and/or saucerisation and additional administration of antibiotics for 6 weeks had even better recovery rates.
Studies in which antibiotic therapy was administered additionally to the surgical intervention had higher recovery rates than studies without antibiotic therapy with one exception. Thus, antibiotic therapy appears to be beneficial for the treatment of osteomyelitis and the recovery of the patients, even more so if it is on the basis of culture specimens. It is however often very difficult and costly to obtain good quality culture specimens. Preferably, these are deep tissue cultures taken intra-operatively and not just superficial swabs. Also, availability and cost are often impediments to good antibiotic treatment.
Data on the economic burden of chronic osteomyelitis were rare and imply that chronic osteomyelitis is common and patients suffering from the disease need a large amount of in-patient care.
Thus, a conclusion about the currently most effective therapy of chronic osteomyelitis in low-income countries cannot be drawn. New insights for possible improvements of new techniques could not be revealed. Further research is needed which should be based on more robust study designs such as randomised control trials or prospective studies with a clearly defined control group to analyse the efficacy of the different treatments of chronic osteomyelitis in low-income countries. From the authors' own experience in Ghana, key issues for a successful treatment of chronic osteomyelitis in these settings are adequate, qualitative imaging, antibiotic therapy based on deep cultures and for the appropriate amount of time and above all aggressive surgical debridement to remove all sequestrae and infected tissue. Hopefully, over time low-and middleincome countries can also benefit from the advancements that are made in the Western world regarding new biomaterials and treatment concepts.
